CLSDQ — Clearside Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- $4.50m
- -$2.30m
- $1.66m
- 21
- 29
- 16
- 10
Annual cashflow statement for Clearside Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.2 | 0.376 | -32.9 | -32.5 | -34.4 |
| Depreciation | |||||
| Non-Cash Items | 3.79 | 4.06 | 8.2 | 13.6 | 11.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.12 | -15.3 | 11.2 | 0.72 | -1.68 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -13.1 | -10.7 | -13.4 | -18.1 | -24.7 |
| Capital Expenditures | -0.055 | 0 | -0.246 | -1.78 | -0.977 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0 | — | — | 0.339 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.055 | 0 | -0.246 | -1.78 | -0.638 |
| Financing Cash Flow Items | 12 | 12.2 | 31.2 | 0.316 | 2.53 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.87 | 23.8 | 31.3 | 0.414 | 16.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.31 | 13 | 17.7 | -19.5 | -8.9 |